Anifrolumab update positive for lupus field – while ImmuPharma’s LupuzorTM could represent a highly successful product

The Life Sciences Division (TLSD), a specialist investment bank to global life sciences companies, today announced an update report on ImmuPharma plc (LON:IMM), a pharmaceutical development company listed on AIM of the London Stock Exchange focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need.

Summary highlights of the update include:

AstraZeneca (LON:AZN) announced topline data from its second Phase III clinical trial in Lupus patients, comparing Anifrolumab, a monoclonal antibody developed for SLE (Systemic Lupus Erythematosus) in a study entitled TULIP II, to the current standard of care (corticosteroids). The Phase III study successfully met both its primary and secondary endpoints – the company briefly stated that the results showed both a statistically significant and clinically meaningful improvement (reduction) in disease activity when compared to standard of care (placebo).

LupuzorTM offers an attractive licensing and development opportunity. It has demonstrated an extremely robust safety profile with a de-risked asset, as evidenced by the 70% response rate in the European cohort of patients from the first Phase III clinical trial (which was statistically significant and clinically meaningful). We believe that this could offer a multitude of advantages over a more traditional monoclonal antibody approach (e.g. Benlysta and Anifrolumab) including better targeting of a Lupus specific pathway, more convenient dosing (subcutaneous not intravenous), better cost of goods and margins, and the ability to offer investors deep value, based on the current market capitalisation of ImmuPharma plc (LON: IMM).

Dr. Navid Malik, Head of Life Sciences Research, (TLSD) said:

“Lupus still represents a major area of unmet medical need and there is a strong need for safe and efficacious products. We believe that the recent update for Anifrolumab is positive for the Lupus field, but also reminds us that LupuzorTM could represent a highly successful product if it successfully navigates a second Phase III clinical trial. Now that we understand the target patient group of Lupus patients who respond best to the drug, we see the path to market as being de-risked.”

The 7 page update research report on ImmuPharma Plc, entitled “AstraZeneca’s AnifrolumabTM successfully navigates the complexity of a Phase III lupus clinical trial, will LupuzorTM be next?” is available to institutional clients by contacting The Life Sciences Division by email on hello@thelifesciencesdivision.com please note this research is restricted to professional clients, and is to be considered non-independent research and should be treated as a marketing communication as it has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research, such restrictions as per the FCA conduct of business sourcebook on investment research.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Immupharma Plc

    More articles like this

    Immupharma Plc

    Learning About Lupus

    May is Lupus Awareness Month. It is a disease that is relatively common in the Caribbean yet many of us are unfamiliar with the condition. Lupus is an autoimmune condition that can affect almost every system

    Immupharma Plc

    ImmuPharma Change of Registered Office Address

    ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today announced that with immediate effect, its registered office address has been changed to: One Bartholomew Close, London, EC1A 7BL.

    Immupharma Plc

    ImmuPharma Change of AGM Venue

    ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, today announced that the Company’s Annual General Meeting confirmed for Thursday, 18 June 2020 @ 10.30am, will now be held at: 52 Grosvenor Garden, London SW1W 0AU. The COVID-19

    Immupharma Plc

    Lupus Latest Facts: Causes, Symptoms and Treatments

    Lupus is a relatively rare inflammatory disease. In the US 1.5 million are currently living with the condition. It is an autoimmune disease that can affect various organs including the skin, joints, kidneys, and brain. What

    Immupharma Plc

    Selena Gomez urges fans to join the fight against Lupus

    US singer Selena Gomez has urged her fans across the world to join the fight against Lupus, an autoimmune disease. The disease leads to the body’s immune system becoming hyperactive, attacking normal and healthy tissues. On

    Immupharma Plc

    Understanding Lupus

    Lupus is a chronic (long-term) disease that can cause inflammation and pain in any part of your body. It’s an autoimmune disease, which means that your immune system — the body system that usually fights infections

    Immupharma Plc

    What to know about COVID-19 and lupus

    Lupus is a chronic autoimmune condition in which the immune system attacks its own tissues. People with lupus are at higher risk of infections, and those with lupus who develop COVID-19 may be at higher risk

    Immupharma Plc

    Frequently asked questions: coronavirus (COVID-19) and lupus

    Our Health Educator Network—health-care professionals and lupus specialists who provide individualized answers—have seen their inquires triple in the last week. The following are questions they’ve been frequently asked and their answers. Should I wear a facemask?

    Immupharma Plc

    Are People with Lupus Protected Against COVID-19?

    There is no evidence that taking hydroxychloroquine (Plaquenil) is effective in preventing a person from contracting the coronavirus (COVID-19). People with lupus should follow the guidance of their doctor and the safety guidelines being issued by

    Immupharma Plc

    Dr Miriam Stoppard on Lupus

    Lupus isn’t that common but when it strikes it can be very ­serious, even life-threatening. The story of the singer and ­actress Selena Gomez is a case in point. All lupus sufferers will be grateful to her because